BNT317
/ BioNTech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 28, 2025
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=39 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1